Advertisement
News
Subscribe to MDT Magazine News

FDA CONSUMER HEALTH INFORMATION - FDA Intends to Remove Unapproved Drugs From Market

March 2, 2011 7:35 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., March 2, 2011 /PRNewswire-USNewswire/ -- Do you use a prescription cough, cold, or allergy relief drug? (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Federal regulators aim to take certain unapproved prescription medicines intended to relieve cough, cold,...

TOPICS:

FDA Prompts Removal of Unapproved Drugs From Market

March 2, 2011 6:39 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., March 2, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today took action against companies that manufacture, distribute, or market certain unapproved prescription oral cough, cold, and allergy products. The affected products cannot be legally...

TOPICS:

Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government

March 2, 2011 6:36 am | by Bio-Medicine.Org | Comments

EAST SETAUKET, N.Y., March 2, 2011 /- Lixte Biotechnology Holdings (OTC: LIXT) announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project (QTDP).  This grant was awarded to further development and commercialization of Lixte's...

TOPICS:
Advertisement

Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference

March 2, 2011 6:35 am | by Bio-Medicine.Org | Comments

CLINTON, N.J., March 2, 2011 /- Ikaria, Inc. today announced that its Chairman and CEO, Daniel Tasse, will present at the 31st Annual Cowen and Company Healthcare Conference on Wednesday, March 9, 2011 at 8:30 a.m. EST.  The conference will be held March 7-9 at the Boston Marriott...

TOPICS:

Unapproved Cough, Cold, Allergy Products: FDA Prompts Removal From Market

March 2, 2011 6:30 am | by U.S. Food & Drug Administration | Comments

Unapproved products have not been evaluated by the FDA for safety, effectiveness, and quality.

TOPICS:

Proton Pump Inhibitor drugs (PPIs): Drug Safety Communication - Low Magnesium Levels Can Be Associated With Long-Term Use

March 2, 2011 5:30 am | by U.S. Food & Drug Administration | Comments

Prolonged treatment with prescription PPIs may lead to low serum magnesium levels, which can result in serious adverse events including muscle spasm (tetany), irregular heartbeat (arrhythmias), and convulsions (seizures).

TOPICS:

e-MDs Continues Track Record of Employee and Revenue Growth

March 2, 2011 4:36 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, March 2, 2011 /- e-MDs, a leading provider of electronic health records (EHRs), is proud to announce another year of record revenue and employee growth.  In 2010 e-MDs doubled their growth rate from the previous two years.  Total employee count grew from 209 to...

TOPICS:

Naviscan Announces European Launch of Positron Emission Mammography

March 2, 2011 4:35 am | by Bio-Medicine.Org | Comments

VIENNA, March 2, 2011 /- Naviscan, Inc., announces the European launch of the Naviscan Positron Emission Mammography (PEM) scanner at two prestigious radiology conferences in Vienna.  On March 3rd, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, a podium...

TOPICS:
Advertisement

PositiveID Corporation Reaches Important Chemistry Milestone in Development of Its GlucoChip(TM) Glucose-Sensing Microchip

March 2, 2011 4:33 am | by PositiveID | Comments

PositiveID Corporation Reaches Important Chemistry Milestone in Development of Its GlucoChip(TM) Glucose-Sensing Microchip

TOPICS:

Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.

March 2, 2011 4:32 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 2, 2011 /- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed an...

TOPICS:

Myriad board approves $100 million buyback plan

March 2, 2011 3:45 am | by The Associated Press | Comments

Myriad Genetics Inc. said Wednesday its board of directors approved a $100 million stock buyback program.The company said it will repurchase $50 million in stock from J.P. Morgan as part of the new program.The remaining $50 million will be repurchased through open market or privately negotiated...

Nile Therapeutics Receives Positive NASDAQ Panel Decision

March 2, 2011 3:35 am | by Bio-Medicine.Org | Comments

SAN MATEO, Calif., March 2, 2011 /- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced that, on March 1, 2011, the Company received a positive determination from the NASDAQ Listing Qualifications...

TOPICS:

Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairs's VistA Imaging System

March 2, 2011 3:34 am | by Bio-Medicine.Org | Comments

MELBOURNE, Fla. and WASHINGTON, March 2, 2011 /- Highlights: System serves more than 1.3 million patients and captures more than 35 million images each month Critical component of VA's mission to provide multimedia patient health records at point of care One of the most comprehensive and...

TOPICS:

Cyberonics Reports Strong Fiscal 2011 Third Quarter Results and Increases Guidance

March 2, 2011 1:36 am | by Bio-Medicine.Org | Comments

HOUSTON, March 2, 2011 /- Cyberonics, Inc. (Nasdaq: CYBX ), a global leader in epilepsy management, today announced results for the quarter ended January 28, 2011.   Quarterly HighlightsOperating results and achievements for the third quarter of fiscal 2011 compared to the third...

TOPICS:

N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting

March 2, 2011 1:34 am | by Bio-Medicine.Org | Comments

BOULDER, Colo., March 2, 2011 /- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. The data describe the preclinical safety evaluation of small molecule...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading